Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233855 | 0.82 | GRM5 (0.46) | GRM5MAOBCYP19A1KMT2ACYP17A1 | |
| SCHEMBL231282 | 0.81 | TSHR (0.61) | GRM5KMT2AALDH1A1 | |
| SCHEMBL28750888 | 0.81 | FFAR4 (0.45) | CYP19A1ALDH1A1 | |
| SCHEMBL10901370 | 0.80 | L3MBTL1 (0.59) | GRM5POLBCYP19A1KMT2AKDM4E | |
| SCHEMBL24937509 | 0.79 | ALDH1A1 (0.48) | GRM5POLBCYP19A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7053203 | 0.79 | TSHR (0.58) | GRM5KMT2AALDH1A1 | |
| SCHEMBL5040591 | 0.79 | CA2 (0.56) | KMT2AALDH1A1 | |
| SCHEMBL4226282 | 0.79 | TSHR (0.58) | GRM5KMT2AALDH1A1 | |
| SCHEMBL19002293 | 0.78 | GRM5 (0.43) | GRM5CYP19A1CYP17A1KDM4E | |
| SCHEMBL361358 | 0.78 | NAPRT (0.61) | GRM5CYP19A1KMT2ACYP17A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023010051-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-0986551-B1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2006-08-02 | — | — | EP | disclosed |
| EP-0928793-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2002-05-15 | — | — | EP | disclosed |
| US-6359134-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| EP-0986551-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| US-6001855-A | REACTING A THIAZOLE DERIVATIVE AND A CYCLIC AMINE DERIVATIVE; INHIBITS BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES OF CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS | HOFFMAN-LA ROCHE INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0928793-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | GRM5, GRM1, GRIN1 | GRM5 1/4885POLB 4131/4885MAOB 2543/4885 |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | GRM5 2005/4885POLB 118/4885MAOB 4400/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | GRM5 2005/4885POLB 118/4885MAOB 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.